Andreoletti Mattia, Haller Luana, Vayena Effy, Blasimme Alessandro
Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
PLOS Digit Health. 2024 May 16;3(5):e0000519. doi: 10.1371/journal.pdig.0000519. eCollection 2024 May.
In the evolving landscape of digital medicine, digital biomarkers have emerged as a transformative source of health data, positioning them as an indispensable element for the future of the discipline. This necessitates a comprehensive exploration of the ethical complexities and challenges intrinsic to this cutting-edge technology. To address this imperative, we conducted a scoping review, seeking to distill the scientific literature exploring the ethical dimensions of the use of digital biomarkers. By closely scrutinizing the literature, this review aims to bring to light the underlying ethical issues associated with the development and integration of digital biomarkers into medical practice.
在数字医学不断发展的格局中，数字生物标志物已成为健康数据的变革性来源，使其成为该学科未来不可或缺的要素。这就需要全面探索这项前沿技术所固有的伦理复杂性和挑战。为满足这一迫切需求，我们进行了一项范围综述，旨在提炼探索数字生物标志物使用伦理维度的科学文献。通过仔细审查文献，本综述旨在揭示与数字生物标志物的开发及其融入医疗实践相关的潜在伦理问题。
